{"id":"NCT00559637","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis","officialTitle":"Single-arm, Open Study to Investigate the Efficacy, Safety and Tolerability of Monthly Subcutaneously Administered C.E.R.A. in Patients With Renal Anemia Not Yet Subject to Dialysis and Not Yet Permanently Treated With ESAs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2007-11-16","resultsPosted":"2016-04-06","lastUpdate":"2016-04-06"},"enrollment":184,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Methoxy polyethylene glycol-epoetin beta","otherNames":["Mircera"]}],"arms":[{"label":"Methoxy polyethylene glycol-epoetin beta","type":"EXPERIMENTAL"}],"summary":"This single arm study will assess the efficacy and safety of subcutaneous Mircera for correction of anemia in participants with chronic kidney disease who are not treated with erythropoiesis stimulating agent (ESA) and not on dialysis. Eligible participants will receive Mircera by monthly subcutaneous injections. The initial dose, based on body weight, will be 1.2 micrograms/kilogram (mcg/kg). The anticipated time on study treatment is 9-11 months, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Percentage of Participants With Both Hemoglobin Values of the Evaluation Phase in the Range of 11-12 Grams Per Deciliter (g/dL)","timeFrame":"Evaluation phase (Months 8 and 9)","effectByArm":[{"arm":"Methoxy Polyethylene Glycol-epoetin Beta","deltaMin":10.67,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":50,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":88,"n":184},"commonTop":["Hypertension","Oedema","Oedema peripheral","Hyperparathyroidism secondary","Vertigo"]}}